Medifast (MED) Stock
Consumer staples company. Here's the price, business snapshot, and what's worth knowing about Medifast in June 2026.
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Medifast's stock with a target price of $21.25, indicating modest growth potential.
Financial Health
Medifast is performing well with strong revenue and cash flow, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
BRITISH AMERICAN TOBACCO SPON ADS EACH REP 1 ORD LVL II
British American Tobacco p.l.c. produces and sells tobacco products, including cigarettes, cigars, electronic cigarettes, and heat-not-burn products.
ARCHER-DANIELS-MIDLAND CO
Archer-Daniels-Midland Company is a global agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. It is a human and animal nutrition provider. Its Ag Services and Oilseeds segment includes global activities related to the origination, merchandising, transportation, and storage of agricultural raw materials, and the crushing and further processing of oilseeds, such as soybeans and soft seeds into vegetable oils and protein meals. Carbohydrate Solutions segment is engaged in corn and wheat wet and dry milling and other activities. Nutrition segment is engaged in the creation, manufacturing, sale, and distribution of a wide array of ingredients and solutions, including plant-based proteins, flavors and colors derived from nature, flavor systems, emulsifiers, soluble fiber, polyols, hydrocolloids, probiotics, prebiotics, postbiotics, enzymes, botanical extracts, and other specialty food and feed ingredients and systems.
BUNGE GLOBAL SA
Processes and merchandises agricultural commodities.
Baskets Featuring MED
The GLP-1 Insurance Gap Reshaping Weight Care in 2026
Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published: 3 June 2026
Explore BasketObesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketModern Grocery Stocks | Berkshire Exits Kraft Heinz
Berkshire Hathaway's plan to sell its major stake in Kraft Heinz signals a larger market trend against legacy packaged foods. This creates an investment opportunity in companies better aligned with modern consumer demands for healthier and private-label options.
Published: 21 January 2026
Explore BasketOral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketCompare Medifast with other stocks
Willi-Food vs Medifast
Willi-Food vs Medifast
Nature's Sunshine vs Medifast
Nature's Sunshine Prods Inc vs Medifast Inc
European Wax Center vs Medifast
European Wax Center vs Medifast
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
